Reported
Lowest–highest estimate
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
R
Ryvu Therapeutics SA
F:9Y4
Ryvu Therapeutics SA
F:9Y4
Price:
3.845
EUR
1.32%
Market Cap:
€88.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Ryvu Therapeutics SA
F:9Y4
|
PL |
|
NV Gold Corp
F:8NV0
|
CA |
|
Tokai Carbon Co Ltd
OTC:TKCBF
|
JP |
|
J
|
Josef Manner & Comp AG
VSE:MAN
|
AT |
|
H
|
Harmonic Inc
F:HMC
|
US |
|
E
|
ENRG Elements Ltd
OTC:EELFF
|
AU |
|
Pan Global Resources Inc
OTC:PGZFF
|
CA |
|
C
|
CVD Equipment Corp
F:0V3
|
US |
|
L
|
Lesaka Technologies Inc
JSE:LSK
|
ZA |
|
Cleantech Vanadium Mining Corp
OTC:CTVFF
|
CA |
|
Hoshizaki Corp
F:HS0
|
JP |
|
Schindler Holding AG
SIX:SCHP
|
CH |
|
Manolete Partners PLC
F:2BE
|
UK |
Wall St Price Targets
9Y4 Price Forecast
Based on 8 analysts
Based on 8 analysts
+144% Upside
from
€3.845
today
Ryvu Therapeutics SA (9Y4)’s 12-month stock price forecast through October 2027 has a consensus target of €9.4, implying 144% upside. The forecast is based on price targets from 8 Wall Street analysts.
Ryvu Therapeutics SA Competitors:
Price Targets
Price Targets
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 9Y4's stock price target?
Price Target
9.4
EUR
9.4
EUR
According to Wall Street analysts, the average 1-year price target for 9Y4 is 9.4 EUR with a low forecast of 5.651 EUR and a high forecast of 10.54 EUR.
What is the Revenue forecast for Ryvu Therapeutics SA?
Projected CAGR
22%
22%
Over the last 12 years, the compound annual growth rate for Revenue has been 14%. The projected CAGR for the next 8 years is 22%.
What is the Gross Profit forecast for Ryvu Therapeutics SA?
Projected CAGR
40%
40%
Over the last 12 years, the compound annual growth rate for Gross Profit has been 23%. The projected CAGR for the next -3 years is 40%.